#Belgium #Leuven #Rewind Therapeutics #GPR17 #Remyelination

Rewind Therapeutics Enhances Advisory Board with Neurology Leaders

In a significant move toward advancing its innovative GPR17 remyelination therapy, Rewind Therapeutics has announced the addition of four prominent experts in neurology to its Scientific Advisory Board (SAB). Renowned for their contributions to neuroimaging and multiple sclerosis (MS) research, Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan bring invaluable expertise that will support the development of groundbreaking therapies for demyelination-associated diseases.

The appointment signals a critical moment for Rewind as it propels the GPR17 modulator through preparations for clinical trials. This novel therapeutic candidate aims to restore myelin, the protective sheath around nerves, utilizing a first-in-class strategy to address a central unmet need in neurodegenerative disorders characterized by myelin loss.

A New Chapter in Multiple Sclerosis Treatment

The challenge of demyelination is particularly pronounced in conditions such as multiple sclerosis, where the body’s ability to repair myelin is severely hampered. Rewind's GPR17 modulator has the potential to reclaim the natural repair mechanisms of the central nervous system, marking a tantalizing frontier in MS treatment.

Dr. Anja Harmeier, CEO of Rewind Therapeutics, emphasized the importance of these appointments, stating, "Rewind's mission is to deliver therapies that harness the central nervous system's natural capacity for self-repair. Each member of our SAB has significantly transformed the understanding and treatment of MS. Their insights will be crucial in designing our clinical strategies that aim to demonstrate the drug's efficacy in a competitive landscape."

Profiles of the SAB Members

1. Prof. Shiv Saidha
- Position: Professor of Neurology at Johns Hopkins University School of Medicine
- Contribution: Recognized for his work in monitoring neuro-axonal damage using optical coherence tomography (OCT) and identifying retinal layer pathology as a predictive marker of MS disease activity.

2. Prof. Cristina Granziera
- Position: Professor of Neurology and Biomedical Engineering at the University of Basel
- Contribution: A pioneer in advanced MRI and neuroimaging, she leads research initiatives focused on neurodegeneration and has received accolades for developing clinically relevant biomarkers.

3. Prof. David Leppert
- Position: Professor of Neurology at the University Hospital Basel
- Contribution: Combines academic rigor with industry experience, including key roles in global MS therapies development. His current work includes validating neuro-axonal injury markers to refine personalized treatment tactics.

4. Prof. Roberto Furlan
- Position: Associate Professor of Medicine at Vita-Salute San Raffaele University
- Contribution: An esteemed neuroimmunologist whose research delves into immune mechanisms of neuroinflammatory diseases, contributing significantly to the understanding of CNS inflammation.

Future Directions

With these esteemed experts on board, Rewind Therapeutics is poised to advance its GPR17 remyelination therapy, with aspirations to provide a transformative approach for treating demyelinating diseases like multiple sclerosis. The collaboration represents a blend of clinical expertise and innovative research that may lead to breakthrough treatments.

"Restoring myelin is a compelling frontier in MS treatment. The targeted GPR17 approach is both scientifically robust and translationally ready," reflected Prof. Saidha, expressing his enthusiasm for the partnership.

As Rewind embarks on this ambitious journey, the commitment to harness cutting-edge science for the betterment of patient outcomes highlights the ongoing evolution of how we can address complex neurological diseases. Investors and stakeholders watch closely as this promising therapy progresses toward clinical development, potentially altering the treatment landscape for millions afflicted by demyelination.

About Rewind Therapeutics

Headquartered in Leuven, Belgium, Rewind Therapeutics is dedicated to developing first-in-class therapeutics aimed at restoring myelin in patients suffering from debilitating diseases such as multiple sclerosis. The importance of remyelination cannot be overstated, as repairing nerve insulation is vital for halting disease progression and improving quality of life for affected individuals. With solid R&D backing and strong investor support, Rewind is at the forefront of pioneering solutions in neurotherapeutics aimed at restoring patients’ health and functionality.